Results 1 to 10 of about 13,840,459 (217)

Predominantly hemorrhagic choroidal neovascular lesion from exsudative age-related macular degeneration treated with intravitreal ranibizumab therapy

open access: yesRevista Brasileira de Oftalmologia, 2013
The authors relate a predominantly hemorrhagic choroidal neovascular lesion from neovascular. Age-related macular degeneration patient case treated with intravitreal ranibizumab therapy.
Miguel Hage Amaro, Aaron Brock Holler
doaj   +2 more sources

Pipeline therapies for neovascular age related macular degeneration [PDF]

open access: yesInternational Journal of Retina and Vitreous, 2021
Age related macular degeneration (AMD) is the most common cause of vision loss in the elderly population. Neovascular AMD comprises 10% of all cases and can lead to devastating visual loss due to choroidal neovascularization (CNV).
Sruthi Arepalli, Peter K. Kaiser
doaj   +3 more sources

Neovascular age-related macular degeneration management – Beyond anti-VEGF [PDF]

open access: yesIndian Journal of Ophthalmology
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has transformed neovascular age-related macular degeneration (nAMD) into a chronic, treatable condition.
Apoorva Ayachit   +7 more
doaj   +2 more sources

Non-invasive testing for early detection of neovascular macular degeneration in unaffected second eyes of older adults: EDNA diagnostic accuracy study

open access: yesHealth Technology Assessment, 2022
Background: Neovascular age-related macular degeneration is a leading cause of sight loss, and early detection and treatment is important. For patients with neovascular age-related macular degeneration in one eye, it is usual practice to monitor the ...
Katie Banister   +11 more
doaj   +1 more source

Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. [PDF]

open access: yesPLoS ONE, 2014
Intravitreal injections of anti-vascular endothelial growth factor agents, such as ranibizumab, have significantly improved the management of neovascular age-related macular degeneration. This study used patient-level simulation modelling to estimate the
Paul Mitchell   +9 more
doaj   +1 more source

Novel approach to antiangiogenic factors in age-related macular degeneration therapy

open access: yesCentral European Journal of Immunology, 2022
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss among the population above 85 worldwide. There are two main types of AMD: neovascular and dry AMD.
Katarzyna Samelska   +4 more
doaj   +1 more source

Bacillary Layer Detachment in Neovascular Age-Related Macular Degeneration: Case Series

open access: yesBiomedicines, 2023
Purpose: This study seeks to report the clinical and multimodal imaging findings of eight eyes of seven patients with neovascular age-related macular degeneration (nAMD) who developed bacillary layer detachment (BALAD).
Filomena Palmieri   +3 more
doaj   +1 more source

Optical Coherence Tomography-Angiography of Different Choroidal Neovascularization Subtypes in Wet Age-related Macular Degeneration

open access: yesFolia Medica, 2019
Age-related macular degeneration is a leading cause of irreversible vision loss in individuals over 55 years of age worldwide. Conventionally, it is divided into two subtypes – dry (non-neovascular) and wet (neovascular) form.
Stavrev Vladimir N.   +2 more
doaj   +1 more source

New Frontiers in Retina: highlights of the 2020 angiogenesis, exudation and degeneration symposium

open access: yesInternational Journal of Retina and Vitreous, 2020
We summarize the most important findings presented at the 2020 angiogenesis, exudation and degeneration symposium in five topic areas: (1) epidemiology of retinal vascular disease and macular degeneration; (2) dry AMD and geographic atrophy; (3 ...
Carmen A. Puliafito, Charles C. Wykoff
doaj   +1 more source

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab

open access: yesInternational Journal of Ophthalmology, 2017
AIM: To report the change in visual acuity and central macular thickness (CMT) following treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration (nAMD) with suboptimum response to ranibizumab ...
Rachel Hui Fen Lim   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy